Relation of Statin Therapy to Risk of Heart Failure After Acute Myocardial Infarction

American Journal of Cardiology

Volumn 102, Issue 12, 2008, Pages 1706-1710

  Aronson, Doron ^a   Mutlak, Diab ^a   Lessick, Jonathan ^a   Kapeliovich, Michael ^a   Dabbah, Salim ^a   Markiewicz, Walter ^a   Beyar, Rafael ^a   Hammerman, Haim ^a   Reisner, Shimon ^a   Agmon, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL;

AGED; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 58949105089     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.07.057     Document Type: Article

References (30)

1. Aronson D., Goldsher N., Zukermann R., Kapeliovich M., Lessick J., Mutlak D., Dabbah S., Markiewicz W., Beyar R., Hammerman H., Reisner S., and Agmon Y. Ischemic mitral regurgitation and risk of heart failure after myocardial infarction. Arch Intern Med 166 (2006) 2362-2368
2. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
3. Zoghbi W.A., Enriquez-Sarano M., Foster E., Grayburn P.A., Kraft C.D., Levine R.A., Nihoyannopoulos P., Otto C.M., Quinones M.A., Rakowski H., et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16 (2003) 777-802
4. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
5. D'Agostino Jr. R.B. Propensity scores in cardiovascular research. Circulation 115 (2007) 2340-2343
6. Lewis E.F., Moye L.A., Rouleau J.L., Sacks F.M., Arnold J.M., Warnica J.W., Flaker G.C., Braunwald E., and Pfeffer M.A. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 42 (2003) 1446-1453
7. Ramasubbu K., Estep J., White D.L., Deswal A., and Mann D.L. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51 (2008) 415-426
8. Levine R.A., and Schwammenthal E. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. Circulation 112 (2005) 745-758
9. Cohn J.N., Ferrari R., and Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35 (2000) 569-582
10. Nahrendorf M., Hu K., Hiller K.H., Galuppo P., Fraccarollo D., Schweizer G., Haase A., Ertl G., Bauer W.R., and Bauersachs J. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol 40 (2002) 1695-1700
11. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., Wen J., and Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
12. Mozaffarian D., Nye R., and Levy W.C. Statin therapy is associated with lower mortality in patients with severe heart failure. Am J Cardiol 93 (2004) 1124-1129
13. Sola S., Mir M.Q., Lerakis S., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
14. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., and Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108 (2001) 1429-1437
15. Tousoulis D., Antoniades C., Vassiliadou C., Toutouza M., Pitsavos C., Tentolouris C., Trikas A., and Stefanadis C. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 7 (2005) 1126-1132
16. Horiuchi M., Cui T.X., Li Z., Li J.M., Nakagami H., and Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107 (2003) 106-112
17. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Tsutsui H., Kaibuchi K., and Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109 (2004) 2234-2239
18. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
19. Go A.S., Lee W.Y., Yang J., Lo J.C., and Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296 (2006) 2105-2111
20. Horwich T.B., MacLellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
21. Foody J.M., Shah R., Galusha D., Masoudi F.A., Havranek E.P., and Krumholz H.M. Statins and mortality in elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
22. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
23. Ray J.G., Gong Y., Sykora K., and Tu J.V. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165 (2005) 62-67
24. Scirica B.M., Morrow D.A., Cannon C.P., Ray K.K., Sabatine M.S., Jarolim P., Shui A., McCabe C.H., and Braunwald E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47 (2006) 2326-2331
25. Bursi F., Enriquez-Sarano M., Jacobsen S.J., and Roger V.L. Mitral regurgitation after myocardial infarction: a review. Am J Med 119 (2006) 103-112
26. Bursi F., Enriquez-Sarano M., Nkomo V.T., Jacobsen S.J., Weston S.A., Meverden R.A., and Roger V.L. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation 111 (2005) 295-301
27. Grigioni F., Detaint D., Avierinos J.F., Scott C., Tajik J., and Enriquez-Sarano M. Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. J Am Coll Cardiol 45 (2005) 260-267
28. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
29. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
30. Smith C.S., Cannon C.P., McCabe C.H., Murphy S.A., Bentley J., and Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J 149 (2005) 444-450